The canonical Wnt signalling pathway induces the b-catenin/lymphoid enhancer factor transcription factors. It is activated in various cancers, most characteristically carcinomas, in which it promotes metastatic spread by increasing migration and/or invasion. The Wnt/b-catenin signalling pathway is frequently activated in melanoma, but the presence of b-catenin in the nucleus does not seem to be a sign of aggressiveness in these tumours. We found that, unlike its positive role in stimulating migration and invasion of carcinoma cells, b-catenin signalling decreased the migration of melanocytes and melanoma cell lines. In vivo, b-catenin signalling in melanoblasts reduced the migration of these cells, causing a white belly-spot phenotype. The inhibition by b-catenin of migration was dependent on MITF-M, a key transcription factor of the melanocyte lineage, and CSK, an Src-inhibitor. Despite reducing migration, b-catenin signalling promoted lung metastasis in the NRAS-driven melanoma murine model. Thus, b-catenin may have conflicting roles in the metastatic spread of melanoma, repressing migration while promoting metastasis. These results highlight that metastasis formation requires a series of successful cellular processes, any one of which may not be optimally efficient.
INTRODUCTION
The canonical Wnt/b-catenin signalling pathway integrates cell-cell and cell-matrix cues into a well-defined transcriptional response. In particular, b-catenin is a multifunctional protein regulating cadherin-associated cell-cell adhesion and transcription mediated by DNA-binding proteins such as T-cell factor/lymphoid enhancer factor (TCF/LEF). The Wnt/b-catenin pathway is activated in many cancers, including carcinoma and melanoma. However, the downstream outcomes are significantly different. In colorectal cancer, high rates of Wnt signalling have been shown to favour both initiation and progression, including metastatic spread, resulting in a poor prognosis. 1, 2 By contrast, for melanoma, an increasingly common highly metastatic disease that is often fatal, patients with high nuclear b-catenin levels have a better prognosis. 3, 4 The different biology of b-catenin activation may be related to the opposing features of epithelial cells and melanocytes. In the classical, carcinoma-centric model, incipient cancer cells, initially locked within the epithelial architecture, first become locally invasive, then reach blood/lymph vessels for metastasis. However, unlike epithelial cells, cells of the melanocytic lineage have intrinsic 'horizontal' migratory properties, a reflection of their colonization of embryonic tissues during development. Thus, for melanomas, the functional effects of b-catenin signalling need to be evaluated not only on invasion and metastasis, but also on migration. In fact, it is even possible that migration needs to be reduced in incipient melanoma cells for them to acquire 'vertical' invasion and metastasis.
Beta-catenin appears to have a variety of roles in melanomagenesis, not only during initiation (increased proliferation and bypassing of senescence) but also during progression. 5 b-Catenin has been shown to inhibit proliferation in murine melanoblasts and human melanoma. 4, 6 However, this protein also promotes melanocyte immortalization by overcoming senescence. 7 Thus, bcatenin modulates the initiation of melanoma through antagonistic effects: inhibiting proliferation, but bypassing senescence.
In vivo, b-catenin is essential for the cell-cell adhesion mediated by cadherins and is required for cell-matrix adhesion. 8 In vitro, the function of b-catenin in invasion has been evaluated, which does not reflect the whole invasion in-vivo process, in various human melanoma cell lines. Depending on the melanoma cell line and protocol used, b-catenin seems to be able either to induce or to repress invasion in vitro. [9] [10] [11] At the molecular level, these discrepancies may best be understood by considering that MITF-M, a target of b-catenin-T-cell factor/lymphoid enhancer factor, has several different functions, depending on its activity. 12 MITF affects the actin cytoskeleton through mDia1 and Rho-GTPases, and the MT1-MMP collagenase (also known as MMP14), thereby affecting invasion. 9, 12 In vivo, the effects of b-catenin signalling on the migration of cells of the melanocyte lineage remain largely unknown. 13 In vitro, the inhibition of GSK-3b by lithium chloride (LiCl) has been shown to prevent the migration of neural crest cells from explanted chicken neural tubes onto fibronectin-coated dishes, 14 which suggests an involvement of b-catenin; however, other cellular targets may be affected by LiCl. Finally, high levels of b-catenin/ lymphoid enhancer factor 1 (LEF1) were correlated with faster cell migration in a panel of six melanoma cell lines, although b-catenin transcriptional activity was not measured, 15 which does not allow to conclude on the role of b-catenin in migration.
Little is known about the role of b-catenin in late stages of metastatic spread. These late stages require a combination of proteins responsible for ensuring survival, adhesion and extravasation at the distant site of spread, together with proliferation and angiogenesis. 16 Recently, it has been shown that b-catenin on a BRAF-PTEN context was inducing metastasis formation, but the mechanism remains fully unknown. 17 A homogeneous genetic background, from the mice to the cells in culture, should improve definition of the complex role of b-catenin during melanomagenesis.
We show here that high b-catenin levels inhibit the migration of cells of the melanocyte lineage (including melanoblasts, melanocytes and melanoma) both in vivo and in vitro. The inhibition of migration is associated with the induction by b-catenin of MITF-M and CSK. b-catenin signalling, despite its inhibitory effects on migration, increases metastatic potential in NRAS-driven melanoma.
RESULTS

LiCl treatment and bcat* expression inhibits the migration of melanocytes in vitro
We first evaluated the strength of b-catenin signalling in a panel of human melanoma cells lines, using the TOP-flash assay. In parallel, we assessed the same panel of human melanoma cell lines for their ability to fill a wound scratch. We observed that the strength of the b-catenin signalling was inversely correlated (Spearman) with the migration of the melanoma cell lines (Figure 1a ). This correlative analysis was corroborated by pharmacological and genetic approaches. Melan-a murine melanocyte cells were treated with LiCl, an inhibitor of GSK-3b, and their migration was measured in a scratch wound assay. Fourteen hours after the scratch, LiCl-treated cells had not migrated as far into the scratch wound as cells treated with sodium chloride, used as controls (Figure 1b) . LiCl-treated cells migrated more slowly during most of the experiment and they had migrated B30% less far than control cells after 14 h (P-valueo10 À 4 ; Figure 1c ). The numbers of cells at the end of the experiment were similar for sodium chloride-and LiCl-treated cells (Supplementary Figure S1A) , so the difference in migration was not due to a difference in cell proliferation. The inhibitory effect of LiCl increased with its concentration (Supplementary Figure S1B) , but we used a low concentration of LiCl (10 mM) to ensure that cell viability was not affected. Indeed, the cell death rate was low and similar to that for sodium chloridetreated controls (Supplementary Figure S1C) . As a control, we verified that LiCl was able to induce the TOP-flash activity, revealing an induction of the Wnt signalling in melan-a cells (Supplementary Figure S1D) .
As LiCl treatment may have effects independent of canonical b-catenin signalling, we then investigated the effect of canonical b-catenin signalling specifically. We analysed the migration of melanocytes transiently transfected with CMV::bcat* or CMV::EGFP (control vector). CMV::bcat* is an expression vector encoding a b-catenin protein tagged with EGFP and stabilized by four serine/ threonine (S/T) to alanine (A) mutations in its N-terminal region. These mutations prevent the phosphorylation of these residues by CK1/GSK-3b, thereby also preventing the subsequent degradation of the protein. 7 This protein also has a nuclear localization signal (NLS), restricting it to the nucleus. Transfected melan-a melanocytes were used to seed a six-well plate at low density, and the migration of the fluorescent, transfected cells was monitored at 4-min intervals for 12 h. Cells transiently transfected with CMV::bcat* migrated at a rate of 14.3±1.6 mm/h, substantially slower ). These findings clearly demonstrate that nuclear b-catenin signalling reduces the migration of melanocytes in vitro.
bcat* inhibits the migration of melanoblasts in vivo We then assessed the effect of canonical b-catenin signalling on the migration of melanoblasts in vivo. Dermal melanoblasts migrate long distances after emerging from the neural tube at around embryonic day (E) 9.0, allowing them to colonize most areas of the skin. In the trunk region of embryos, melanoblasts migrate dorsolaterally from the neural tube to reach the most ventral part. Consequently, mutations reducing melanoblast migration often result in a 'white belly-spot' phenotype. We investigated bcat* mice, which produce the stabilized, nuclear b-catenin described above under the control of a tyrosinase promoter, restricting the production of this protein to the melanocyte lineage (Figure 3a) . 7 bcat* mice had a white belly spot (Figures 3b and c ) that covered B28±8% of the belly area between the four limbs. The white belly-spot phenotype was fully penetrant and not due to a mouse founder effect: all bcat* mouse lines developed from different founders had a white belly spot, as did a mouse line developed with a different bcat* construct that did not contain an NLS (Supplementary Figures S2A-F) .
To confirm that the white belly spot was caused by a lack of melanocytes in the affected area (as opposed to a lack of tyrosinase or other essential melanogenesis proteins, or a failure of melanin transport in melanocytes, or melanin transfer from melanocytes to surrounding keratinocytes), we tested for the presence of melanoblasts/melanocytes in the ventral belly region of bcat* embryos and mice. We used Dct::LacZ mice, in which X-gal staining can be used to identify the melanocyte lineage. .
b-Catenin, migration and metastasis SJ Gallagher et al from the white belly region of bcat* mice at postnatal day (p) 8 (data not shown), further confirming that the white belly spot is caused by a lack of melanocytes, rather than an inability to produce or transfer melanin. Although fully penetrant, the white belly spot in bcat* mice varied in size and shape (Supplementary Figures S2A-C) . This variation could be attributed to natural variation between mice, with the extent of melanoblast colonization of the ventral belly area at E16.5 varying between individual bcat*-LacZ embryos (Supplementary Figures S2G-J) . Such variation was also observed in WT-LacZ embryos ( Supplementary  Figures S2K-N) .
We then investigated the effect of bcat* on the distance melanoblasts had migrated at different stages of embryogenesis. The migration of melanoblasts from the neural tube commences around E9.0 and is completed at around E16.0. At E10.5, melanoblasts have only recently exited the migration staging area and the bcat* transgene has just started to be expressed from the tyrosinase promoter (commencing around E10, 19 ). At E10.5, the advancing front of melanoblasts in bcat*-LacZ embryos was only slightly behind that of WT-LacZ embryos (Figures 3f and g ). At E13.5, melanoblasts in WT-LacZ embryos had migrated further along the dorsolateral pathway than in bcat*-LacZ embryos, and this difference was even larger at E14.5: in embryos expressing bcat* the melanoblasts had not colonized the belly region, by contrast to what was observed for WT-LacZ embryos (Figures 3f-n) . We measured the distance covered by migrating melanoblasts in bcat* and WT embryos, on transverse sections cut from X-gal-stained WT-LacZ and bcat*-LacZ embryos between stages E12.5 and E15.5. The distance from the dorsal tip of the embryo to the most advanced melanoblast was measured in the region between somites 16 and 23 (Figures 3l and m) . The distance migrated by the most advanced melanoblast increased roughly linearly with time in both mouse types. At E15.5, the most advanced melanoblast was 7.3 mm from the dorsal tip of the embryo in WT-LacZ embryos, but only 5.4 mm (26% less) from the dorsal tip in bcat*-LacZ embryos (Figure 3n ). This corresponds to an apparent average migration speed of 1.2 mm/ day for bcat* mice and 1.7 mm/day in WT C57BL/6 mice for melanoblasts between E12.5 and E15.5 (P-value ¼ 0.037). These data strongly suggest that canonical b-catenin signalling reduces the migration of melanoblasts in vivo, causing a decrease in migration soon after the initiation of signalling that is maintained during embryogenesis.
Melanocyte cell lines established from bcat* mice migrate more slowly in vitro Melanoblasts migrate slower in bcat* mice than in wild-type (WT) controls. We then investigated the possible impairment of migration when the melanoblasts had differentiated into melanocytes. As melanocytes in vivo display limited migration that is difficult to detect, we investigated immortalized melanocyte cell lines established in our laboratory from neonates of WT and bcat* littermates. This also made it possible to carry out a preliminary investigation of the potential targets interacting with b-catenin in the reduction of migration. For example, b-catenin signals through MITF-M, which alters the cell cytoskeleton by activating mDia1 expression, stimulating peripheral actin assembly and decreasing cell movement. 12 The bcat* and WT melanocyte cell lines established from mutant and WT littermate neonates have been described before. 7 As expected, both mRNAs and proteins for MITF-M and mDia1 were less abundant in WT than in bcat* melanocyte cell lines (Figure 4a; Supplementary Figure S3) . The TOP-flash activity in WT melanocytes indicates that b-catenin is transcriptionally active. Such TOP-flash activity is slightly but significantly induced in bcat* melanocytes (Figure 4b ). As seen in vivo, WT melanocytes migrated faster than bcat* melanocytes in a random migration assay (Figure 4c ).
b-Catenin signals through MITF-M to reduce migration
We then investigated the contribution of MITF-M to reduce migration in response to bcat* signalling in human melanoma cells. For these experiments, we used the human Mull melanoma cell line, which expresses b-catenin weakly and MITF-M moderately. As expected, transient bcat* expression reduced the random migration of these cells from 27.8 ± 1.9 to 12.0 ± 1.4 mm/h (Figure 5a ). When MITF-M levels were decreased by an siRNA, the cells migrated at about the same speed as control siRNAtreated cells (26.8 ± 1.9 mm/h). The expression of bcat* reduced the migration speed of Mull cells in which MITF-M was eliminated by siRNA to 17.4±2.2 mm/h, a smaller decrease ( À 35%) than that for cells with normal levels of MITF-M ( À 57%). Western blotting confirmed that the siRNA treatment eliminated MITF-M protein and that bcat* was produced (Supplementary Figure 5B) . As only 5-10% of Mull cells transfected with CMV::bcat* produced the protein, we did not expect the effect of bcat* on MITF-M level to be detectable on western blotting. As expected, we revealed by immunofluorescence that bcat* induces MITF (Supplementary Figure S4) . From these experiments, we concluded that although b-catenin signals through MITF-M to reduce the migration of melanoma cells, there must be other targets independent of MITF-M. We investigated this possibility in vivo, by crossing bcat* mice with mice of the MITF vga9/ þ genotype. MITF vga9/ þ mice have one defective MITF allele, and have either no belly spot, or in rare cases, a small white belly spot. Crossing bcat* mice onto an MITF vga9/ þ background resulted in mice with white belly spots of the same size as those in bcat* mice (Supplementary Figure 5C) . This result suggests that the reduction of melanoblast migration by b-catenin during embryogenesis does not result solely from an increase in MITF-M levels and that there are, therefore, other, MITF-M-independent targets. 20 From these 988 target genes, an Ingenuity Pathway Analysis was performed. Functional Ingenuity Pathway Analysis terms for 'cell movement', 'cell-to-cell interaction' and 'angiogenesis' were chosen to generate a list of 211 b-catenin target genes. Second, we searched for genes differentially regulated between melanoma cell lines identified as having 'proliferative' and 'invasive' signatures. 21 Expression data from six laboratories were analysed with the online tool developed by Hoek (http://www.jurmo.ch/php/genehunter.html). Six genes (BCL2, SHC1, NF1, CSK, ADAM9 and NRG2) were differentially expressed between the 'proliferative' and 'invasive' groups in at least two data sets from the six laboratories. These six genes are b-catenin targets, known to be involved in cell movement, cell-to-cell interaction or angiogenesis, and associated with 'proliferative' and 'invasive' signatures in melanoma cell lines (Supplementary Figure S5) . We correlated the level of expression of the six genes, estimated by q-RT-PCR, in a panel of seven human melanoma cells lines, with the TOP-flash activity of the cells (Supplementary Figure S6) and with their potential to close a wound (Supplementary Figure S7) . With a correlation cutoff of r4 þ 0.5 or ro À 0.5, it appears that the expression of CSK, SHC1 and NF1 is correlated/anti-correlated with the activity of b-catenin. With a correlation cutoff of r4 þ 0.5 or ro À 0.5, it appears that the expression of CSK, NF1 and ADAM9 is correlated/anticorrelated with the potential of the cells to close the wound. We focussed on CSK, a negative regulator of SRC, a key kinase regulating cell migration. 22 As expected, b-catenin was able to induce the level of CSK protein (data not shown). We evaluated the ability of CSK to affect migration of human melanoma cells. Wound scratch analysis showed that in the presence of siCSK (siRNA directed against CSK), melanoma cells were able to close the wound faster than in the presence of control siRNA (Figures 6a  and b) . In the presence of siCSK, the level of SRC phosphorylated at the level of tyrosine 527 is less abundant (Figure 6c ). Given the role of SRC in migration, the reduction of this phosphorylated form may explain the induction of migration.
b-Catenin signalling may increase the metastatic potential of melanoma We also investigated the impact of canonical b-catenin signalling on the metastatic potential of murine melanoma in vivo, by crossing bcat* mice onto a Tyr::Nras Q61K background. Mice containing the Tyr::Nras Q61K transgene produce oncogenic, activated NRAS in the melanocyte lineage, which is known to induce proliferation, and develop melanoma after a long lag period, with moderate penetrance. 23 We crossed bcat* mice onto a Tyr::Nras Q61K genotype and the resulting Tyr::Nras Q61K /1; bcat*/1 ( ¼ Nras;bcat*) mice developed melanoma with a higher rate of penetrance and shorter latency than Tyr::Nras Q61K /1 ( ¼ Nras) mice. 7 However, these mice had a white belly spot, suggesting that the migration of melanoblasts is still impaired, even on an Nras background (Supplementary Figure S8) . Primary melanomas in both Nras and Nras;bcat* mice were allowed to grow until the mouse was moribund. An autopsy was then performed, searching for metastases. Against expectation, a higher proportion of Nras;bcat* mice (3/17; 18%) than Nras mice (1/26; 4%) developed distant metastases (Supplementary Figure 7A) , suggesting that bcat* promotes lung metastasis in Nras mice.
Thus, it appears that b-catenin signalling inhibits the initial stages of metastatic spread by reducing cell migration, but facilitates later stages of metastatic spread by promoting survival/ proliferation, implantation and/or angiogenesis. We investigated b-Catenin, migration and metastasis SJ Gallagher et al late melanoma progression, by injecting cells derived from Nras or Nras-bcat* primary melanoma tumours into the tail vein of immunodeficient mice and evaluating the ability of these cells to form multiple lung metastases. As the melanoma cells were injected directly into the bloodstream, the initial migration and invasion steps were bypassed, and the lung was the primary site at which the injected cells formed tumours. Multiple lung metastases were observed in 8% (1/13) of mice injected with Nras cells and 39% (9/23) of mice injected with Nras-bcat* cells (Figure 7b ). The mean number of tumours in mice developing lung metastases was also higher in mice injected with Nras-bcat* than in mice receiving Nras tumour cells (12 vs 3, P-value ¼ 0.024; Figures 7c  and d ). These findings suggest that bcat* signalling favours certain aspects of the process of metastatic spread.
DISCUSSION
In colorectal, liver, lung and breast cancers, b-catenin promotes migration, invasion and proliferation. It was therefore not unreasonable to expect b-catenin to act similarly in the melanocyte lineage. However, it has now been clearly demonstrated that b-catenin signalling does not fully mimic all these processes in the melanocyte lineage. Instead, in this lineage b-catenin has been shown to alter invasion in vitro 9-11 and proliferation; 4,7,9 here we show, additionally, that b-catenin also inhibits migration.
The negative effect of b-catenin on migration is important when seen in the context of the melanocytic lineage because it highlights critical differences in the biology of epithelial cells and melanocytes. In fact, epithelial cells are normally locked-in in the organized architecture of the epithelium and cell-cell and cellmatrix adhesion are mediated by b-catenin's structural role; thus, incipient carcinoma cells in addition to increased proliferation/ reduced apoptosis must acquire properties of local invasiveness and increased migration to reach lymphatic and blood vessels for distant metastasis; b-catenin activation stimulates both properties in carcinoma cells. To the contrary, cells of the melanocytic lineage are not organized in a multicellular architecture requiring the structural function of b-catenin and in fact have intrinsic migratory properties from early development during colonization of the skin; here, we show that b-catenin activation remarkably reduces migration in cells of the melanocytic lineage (from melanoblasts to melanocytes to melanomas). Despite the ambiguous behaviour of b-catenin in migration and invasion of melanocytic lineages, we found it surprising that activation of b-catenin seems to result in increased metastatic potential in both epithelial and melanocytic lineages. In our homogeneous NRAS;bcat* model, a possible explanation for increased metastatic potential compared with NRAS model would depend on a combination of various cellular mechanisms including migration, matrix degradation and proliferation, but also survival, adhesion (cell-cell and cell-matrix) and angiogenesis.
Since melanomas may have an intrinsic metastatic potential, it is possible that the environmental context of the primary melanoma may determine whether b-catenin signalling drives or suppresses metastatic spread. The spread of tumours surrounded by extensive matrix and cellular barriers may be impeded by b-catenin signalling, through a decrease in migration and invasion. Conversely, the pro-survival signals, cell adhesion and angiogenesis signals induced by b-catenin may favour tumour spread for tumours located close to lymphatic or vascular systems, which do not require such high levels of invasiveness for the initiation of metastatic spread. This is certainly consistent with our data showing that Nras;bcat* tumours are more aggressive than controls when injected into the tail vein of Nude mice. In this experimental model, the initial requirements for migration and invasion are bypassed and cell survival, attachment and growth at distant sites are the primary determinants of aggressive behaviour. In the future, b-catenin-specific targets involved in these three processes will have to be identified and validated with appropriate biological tests, including mouse models. Differences in the biology of b-catenin in epithelial cells and melanocytes and, in particular, the dual nature of b-catenin signalling in melanoma, may eventually reflect in the different significance of b-catenin function and activation in the natural history and progression of carcinomas and melanomas. While b-catenin activation in carcinomas is invariably associated with poor prognosis, 1,2 the relationship among b-catenin signalling, disease progression and patient survival is more complex in melanoma. Several studies have shown that nuclear b-catenin levels decrease as melanoma progresses, this decrease being associated with a better prognosis. 3, [24] [25] [26] Conversely, other studies have reported that b-catenin increases migration, proliferation and survival and that nuclear b-catenin is found in one third of metastatic melanomas. 10, 15, 26, 27 This work highlights the pro-and anti-metastatic potential of b-catenin. Here, using the same and homogeneous genetic context, we showed that b-catenin can inhibit proliferation and migration, but that this protein also induce immortalization and metastasis during melanomagenesis. b-catenin thus appears to be an essential modulator during melanomagenesis.
The opposite patterns of behaviour observed for b-catenin signalling in the melanocyte lineage and in carcinoma may be accounted for in part by MITF-M signalling, which is absent from other cell lineages. MITF-M has been shown to have a critical role in the reduction of melanoma invasiveness by b-catenin and in colon cancer cell lines in which MITF-M is produced ectopically. 9 We show here that the inhibition of migration by b-catenin signalling displays only partial dependence on MITF-M. The mechanism by which MITF-M inhibits melanoma cell migration and invasiveness has not been fully elucidated, but certainly involves some MITF-M target genes. 9, 12 Moreover, it has been shown that b-catenin and MITF-M interact and that the expression of MITF-M and b-catenin target genes can be affected by this protein-protein interaction. 6, 28 We showed that CSK, as a b-catenin target and an inhibitor of Src, (known to induce migration), can induce melanoma cell migration when it is repressed. This finding is certainly of importance, it shows that the induction of the Wnt pathway may repress migration through at least two proteins, which are M-Mitf and CSK. M-Mitf is certainly not a simple protein to target, because, depending on its activity its function is capricious. 12 Being a kinase, CSK is certainly targetable and theoretically can be repressed or induced. Using 'Scratch wound assay automatic analysis' macros that we developed (see Materials and methods), it would be very easy to screen a large amount of chemicals for their ability to affect migration. Such potential activator/repressor of CSK would affect cell migration and in consequence melanoma progression.
In summary, we show here that, opposite to its role in epithelial lineages and carcinomas, b-catenin signalling may inhibit the migration of all cells of the melanocyte lineage: melanoblasts, melanocytes and melanoma cells. However, much like carcinomas, we clearly show that b-catenin activation promotes metastasis of melanomas in vivo. Targeting the b-catenin pathway is an attractive approach for the treatment of melanoma, and chemical inhibitors and activators of this pathway have already been identified. However, b-catenin signalling may have both positive and negative effects on melanomas, depending on cell context, so careful consideration is required when contemplating the use of such treatments.
MATERIALS AND METHODS
Cell lines and migration assays
WT (9v and melan-a) and bcat* (10d) melanocyte cells lines were previously described. Confluent cells were wounded by scratching with a 200-ml yellow pipette tip and medium replaced. Cells were imaged every 30 min for 14 h, and the distance migrated was evaluated by measuring the size of the wound with ImageJ software, using the 'Scratch wound assay automatic analysis' macros from http://imagejdocu.tudor.lu/doku.php?id=plugin:analysis:scratch_wound_assay_automatic_analysis_macro:start. Cell viability and numbers were assessed by trypan blue staining and counting in a haemocytometer.
Exponentially growing cells were seeded at a density of 3.5 Â 10 4 in a six-well plate. After 20 h of incubation, the medium was replaced by 12-Otetradecanoylphorbol-13-acetate-free medium. The cells were incubated for a further 5 h and then imaged every 4 min for 12 h. The nucleus of each cell was manually tracked with the Manual Tracking plugin for ImageJ. Experiments were performed three times, with at least 80 cells tracked for each treatment.
About 3 Â 10 5 cells were transfected with 2 mg CMV::bcat*, CMV::EGFP, 40 nM siRNA against MITF (100 nM siRNA against CSK) or non-targeting siRNA pool from Dharmacon (Chicago, IL, USA). The following day, cells were released from the plates by trypsin digestion and used to seed fresh six-well plates, at a density of 1 Â 10 5 cells per well. The cells were allowed to adhere for 16-20 h and imaged. Experiments were performed three times, with at least 80 cells tracked for each treatment.
Transgenic mice and tail-vein injections
Mice were previously described. 7, 23 All animals were housed in specific pathogen-free conditions at Institut Curie, in accordance with French and European Union law.
Tail-vein injection experiments were performed on nu/nu mice obtained as described elsewhere. 30 Small pieces (8 mm 3 ) of primary tumours from Nras or (Nras;bcat*) mice were initially implanted subcutaneously into the neck-pad of a nu/nu mouse. When the implanted tumour had attained a volume of about 1 cm 3 , it was removed and the cells were dissociated. We then injected 2.5 Â 10 5 viable (trypan blue negative) into the tail vein of nu/nu mice and followed the mice for 80-150 days. The mice were then killed humanely and an autopsy was carried out, with investigation of the lungs for tumours.
Staining of embryonic melanoblasts
Melanoblasts were visualized and located as previously described. 6, 18 At least 20 sections, evenly spaced between somites 16 and 23, were viewed for each embryo, and the distance migrated by the most advanced melanoblast was measured from the dorsal tip of the embryo. Several embryos (from 3 to 5) were analysed for each genotype and embryonic stage from E12.5 to E15.5. The area of the white belly spot of adult mice was calculated as a ratio of spot area to total belly area between the four limbs, and is expressed as a percentage. ImageJ software was used to measure the sizes of the belly and white belly spot.
Real-time RT-PCR, western blotting and antibodies
Total RNA was extracted and real-time RT-PCR carried out as previously described. 30 The primer sequences are given in Supplementary Table 1 . Western blots were performed as previously described. 7 The antibodies used were specific for b-actin (AC-15; Sigma, St Louis, MO, USA), b-catenin (ab6302; Abcam, Cambridge, MA, USA), mDia-1 (clone 51; BD Transduction Labs, Franklin Lakes, NJ, USA), MITF-M (C5; Abcam), GFP (ab290; Abcam), a-tubulin (DM1A; Sigma), phospho-Src (Tyr527) (2105; Cell Signaling, Danvers, MA, USA), phosphor-Src (Tyr416) (2101; Cell Signaling), Src (2101; Cell Signaling) and CSK (HPA028425; Sigma).
